Reply to 'Safety profile of capecitabine as maintenance treatment after XELOX or FOLFOX in metastatic colorectal cancer patients' by C. Cremolini et al

Ann Oncol. 2016 Sep;27(9):1810-1. doi: 10.1093/annonc/mdw212. Epub 2016 May 18.

Authors

H Y Luo¹, R H Xu²

Affiliations

¹ Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China.
² Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China [email protected].

PMID: 27194813
DOI: 10.1093/annonc/mdw212

No abstract available

Publication types

Letter
Comment

MeSH terms

Antineoplastic Combined Chemotherapy Protocols
Capecitabine*
Colorectal Neoplasms
Deoxycytidine / analogs & derivatives
Fluorouracil* / analogs & derivatives
Humans
Leucovorin
Organoplatinum Compounds
Oxaloacetates

Substances

Organoplatinum Compounds
Oxaloacetates
Deoxycytidine
Capecitabine
Leucovorin
Fluorouracil

Supplementary concepts

XELOX